Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZNTL
stocks logo

ZNTL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.439
-33.55%
--
--
-0.418
-37.61%
--
--
-0.440
+18.92%
Estimates Revision
The market is revising No Change the revenue expectations for Zentalis Pharmaceuticals, Inc. (ZNTL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.00%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.49%
In Past 3 Month
Stock Price
Go Down
down Image
-20.00%
In Past 3 Month
Wall Street analysts forecast ZNTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZNTL is 6.60 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ZNTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZNTL is 6.60 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.400
sliders
Low
4.00
Averages
6.60
High
10.00
Current: 1.400
sliders
Low
4.00
Averages
6.60
High
10.00
Morgan Stanley
Michael Ulz
Equal Weight
downgrade
$8 -> $4
2025-11-11
Reason
Morgan Stanley
Michael Ulz
Price Target
$8 -> $4
2025-11-11
downgrade
Equal Weight
Reason
Morgan Stanley analyst Michael Ulz lowered the firm's price target on Zentalis to $4 from $8 and keeps an Equal Weight rating on the shares after the company reported Q3 earnings and highlighted progress with enrollment ongoing in the DENALI Part 2a study for azenosertib in platinum resistant ovarian cancer. The firm has fine tuned its azenosertib revenue estimates, having increased its PROC revenue estimate, removed revenues from non-gynecological indications and decreased its peak sales estimate to $511M from $867M previously.
Wells Fargo
Equal Weight
downgrade
$6 -> $5
2025-08-07
Reason
Wells Fargo
Price Target
$6 -> $5
2025-08-07
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Zentalis to $5 from $6 and keeps an Equal Weight rating on the shares. The firm says it remains on the sidelines due to Zentalis' lack of catalysts as azeno's DENALI Part 2a/b top line data in CCNE1+ PROC won't be reported until year-end 2026.
Oppenheimer
Oppenheimer
Outperform
maintain
$10 -> $9
2025-05-15
Reason
Oppenheimer
Oppenheimer
Price Target
$10 -> $9
2025-05-15
maintain
Outperform
Reason
Oppenheimer lowered the firm's price target on Zentalis to $9 from $10 and keeps an Outperform rating on the shares after quarterly results and catching up with management. The firm believes Azenosertib is a drug that will help people with ovarian cancer. While Oppenheimer acknowledges the company likely won't have any major clinical milestones, it notes that it should have an important regulatory milestone: FDA buy-in on a confirmatory trial design-which would mean implicit confirmation of azenosertib's proposed accelerated approval pathway.
Wedbush
Robert Driscoll
Hold
Reiterates
$4
2025-03-28
Reason
Wedbush
Robert Driscoll
Price Target
$4
2025-03-28
Reiterates
Hold
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$10
2025-03-27
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$10
2025-03-27
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$10
2025-03-17
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$10
2025-03-17
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zentalis Pharmaceuticals Inc (ZNTL.O) is -0.80, compared to its 5-year average forward P/E of -5.61. For a more detailed relative valuation and DCF analysis to assess Zentalis Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.61
Current PE
-0.80
Overvalued PE
-1.35
Undervalued PE
-9.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.65
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.28
Undervalued EV/EBITDA
-7.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
232.92
Current PS
0.00
Overvalued PS
1268.65
Undervalued PS
-802.81
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ZNTL News & Events

Events Timeline

(ET)
2025-11-10
16:27:19
Zentalis Announces Q3 Earnings Per Share of 37 Cents, Below Consensus Estimate of 48 Cents
select
2025-09-24 (ET)
2025-09-24
15:35:12
Zentalis Board Member Letai Emerges as Top Candidate for NCI Leadership, According to STAT
select
link
2025-08-26 (ET)
2025-08-26
16:09:52
Zentalis Announces Departure of CLO Andrea Paul, James Bucher to Take Over
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-04Newsfilter
Zentalis Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • Stock Options Granted: Zentalis Pharmaceuticals granted non-qualified stock options to a newly hired employee, totaling 17,000 shares, under its 2022 Employment Inducement Incentive Award Plan.

  • Exercise Price and Vesting: The stock options have an exercise price of $1.44 per share, with a 10-year term and a vesting schedule that includes 25% vesting after one year and the remainder vesting monthly over three years.

  • Company Overview: Zentalis is a clinical-stage biopharmaceutical company focused on developing azenosertib, a WEE1 inhibitor for ovarian cancer and other tumor types, which has shown promise in clinical trials.

  • Research and Development: The company is exploring additional applications for azenosertib beyond platinum-resistant ovarian cancer, leveraging its expertise in biopharmaceutical research.

[object Object]
Preview
1.0
11-03Newsfilter
Zentalis Pharmaceuticals Set to Attend Upcoming Investor Conferences

  • Upcoming Investor Conferences: Zentalis Pharmaceuticals will participate in the Guggenheim's 2nd Annual Healthcare Innovation Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025, with live webcasts available on their website.

  • Azenosertib Development: The company is developing azenosertib, a potentially first-in-class WEE1 inhibitor for ovarian cancer and other tumor types, which has shown anti-tumor activity and good tolerance in clinical trials.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the potential of azenosertib and the company's future, highlighting risks and uncertainties that could affect actual results.

  • Company Information: Zentalis Pharmaceuticals is based in San Diego and focuses on advancing research for azenosertib beyond its current applications in platinum-resistant ovarian cancer.

[object Object]
Preview
9.0
10-14Newsfilter
Zentalis Pharmaceuticals to Showcase Four Azenosertib Posters at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  • Zentalis Pharmaceuticals Announcement: Zentalis Pharmaceuticals has announced that four abstracts related to their WEE1 inhibitor, azenosertib, have been accepted for presentation at the AACR-NCI-EORTC International Conference, highlighting its potential in treating Cyclin E1-positive platinum-resistant ovarian cancer.

  • Clinical Trial Insights: The presentations will cover Phase 1 results and ongoing studies, emphasizing azenosertib's role as a monotherapy and in combination therapies, with a focus on its biomarker-driven strategy for underserved patient populations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zentalis Pharmaceuticals Inc (ZNTL) stock price today?

The current price of ZNTL is 1.4 USD — it has increased 1.45 % in the last trading day.

arrow icon

What is Zentalis Pharmaceuticals Inc (ZNTL)'s business?

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.

arrow icon

What is the price predicton of ZNTL Stock?

Wall Street analysts forecast ZNTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZNTL is 6.60 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zentalis Pharmaceuticals Inc (ZNTL)'s revenue for the last quarter?

Zentalis Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Zentalis Pharmaceuticals Inc (ZNTL)'s earnings per share (EPS) for the last quarter?

Zentalis Pharmaceuticals Inc. EPS for the last quarter amounts to -0.37 USD, decreased -33.93 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zentalis Pharmaceuticals Inc (ZNTL)'s fundamentals?

The market is revising No Change the revenue expectations for Zentalis Pharmaceuticals, Inc. (ZNTL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.00%.
arrow icon

How many employees does Zentalis Pharmaceuticals Inc (ZNTL). have?

Zentalis Pharmaceuticals Inc (ZNTL) has 166 emplpoyees as of December 05 2025.

arrow icon

What is Zentalis Pharmaceuticals Inc (ZNTL) market cap?

Today ZNTL has the market capitalization of 101.51M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free